

18810-81552

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Cohn *et al.*

Serial No.: 09/898,165

Filed: July 2, 2001

For: **3-PHOSPHOADENOSINE-5-PHOSPHOSULFATE (PAPS)  
SYNTHETASE PROTEINS AND METHODS FOR TREATING  
OSTEOARTHRITIC DISORDERS**

Examiner: Saidha, T.

Art Unit: 1652


**DECLARATION OF DR. DANIEL H. COHN****UNDER 37 C.F.R. § 1.131**

1. I, Daniel H. Cohn, residing at 538 14<sup>th</sup> St., Santa Monica, CA 90402, declare that I have personal knowledge of the facts averred herein.

2. I am a named co-inventor of the invention described and claimed in U.S. Patent Application Ser. No. 09/898,165 for 3-PHOSPHOADENOSINE-5-PHOSPHOSULFATE (PAPS) SYNTHETASE PROTEINS AND METHODS FOR TREATING OSTEOARTHRITIC DISORDERS, filed on July 2, 2001, which is a division of U.S. Serial No. 09/399,212, filed September 17, 1999 (now abandoned). In addition, Dr. Muhammad Faiyaz ul Haque, Ms. Lily M. King, and Dr. Deborah Krakow are named co-inventors of the aforementioned patent application. Together Dr. Haque, Ms. King, Dr. Krakow, and I are the sole inventors of the claimed invention.

3. On May 22, 1998, I executed an Invention Disclosure Form to my employer, Cedars-Sinai Medical Center, disclosing the claimed invention (appended as Exhibit 1). This document evidences that the claimed invention was reduced to practice before May 22, 1998, and prior to the publication dates of two reference cited by the Examiner, i.e., Franzon *et al.*, Int'l J. of Biochem. & Cell Biol. 31:613-26 (May 1999) and Falco *et al.*, U.S. Patent No. 6,338,966, claiming priority from provisional application 60/092,833 filed on July 14, 1998.

4. I further aver that the invention claimed in the above-referenced application was conceived and reduced to practice in the United States of America, in particular, at Cedars-Sinai Medical Center, Los Angeles, CA.

 11/13/03  
Daniel H. Cohn Date

Co-Director,  
International Skeletal Dysplasia Registry  
Cedars-Sinai Medical Center